secwatch / observer
8-K filed February 20, 2025, 6:59 PM ET ticker KYNB CIK 0000921299
M&A confidence high sentiment positive materiality 0.90

FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027

KYNTRA BIO, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christine L. Chung

Senior Vice President, China Operations
KYNB · KYNTRA BIO, INC.
Filed
February 20, 2025, 6:59 PM ET
Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christine L. Chung departed as Senior Vice President, China Operations at KYNTRA BIO, INC..

Action
cease employment
Role
Senior Vice President, China Operations
Exact text from the filing
Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.
View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR
accession 0000950170-25-023729
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.